LIGAND PHARMACEUTICALS (LGND) Stock Fundamental Analysis
USA - NASDAQ:LGND - US53220K5048 - Common Stock
200.22 USD
+9.84 (+5.17%)
We assign a fundamental rating of 5 out of 10 to LGND. LGND was compared to 192 industry peers in the Pharmaceuticals industry. LGND is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. LGND is growing strongly while it is still valued neutral. This is a good combination!
1. Profitability
1.1 Basic Checks
LGND had positive earnings in the past year.
In the past year LGND had a positive cash flow from operations.
In multiple years LGND reported negative net income over the last 5 years.
In the past 5 years LGND always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of LGND (-8.00%) is better than 69.79% of its industry peers.
With a decent Return On Equity value of -9.16%, LGND is doing good in the industry, outperforming 74.48% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8% | ||
| ROE | -9.16% | ||
| ROIC | N/A |
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
LGND's Operating Margin has declined in the last couple of years.
The Gross Margin of LGND (93.05%) is better than 95.31% of its industry peers.
In the last couple of years the Gross Margin of LGND has remained more or less at the same level.
LGND does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 93.05% |
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
2. Health
2.1 Basic Checks
LGND does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LGND has more shares outstanding
LGND has more shares outstanding than it did 5 years ago.
The debt/assets ratio for LGND is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 19.84 indicates that LGND is not in any danger for bankruptcy at the moment.
LGND has a Altman-Z score of 19.84. This is amongst the best in the industry. LGND outperforms 91.67% of its industry peers.
LGND has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 19.84 |
ROIC/WACCN/A
WACC8.84%
2.3 Liquidity
A Current Ratio of 5.45 indicates that LGND has no problem at all paying its short term obligations.
LGND's Current ratio of 5.45 is fine compared to the rest of the industry. LGND outperforms 71.88% of its industry peers.
A Quick Ratio of 5.21 indicates that LGND has no problem at all paying its short term obligations.
LGND's Quick ratio of 5.21 is fine compared to the rest of the industry. LGND outperforms 70.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.45 | ||
| Quick Ratio | 5.21 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 20.80% over the past year.
Measured over the past years, LGND shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.44% on average per year.
LGND shows a strong growth in Revenue. In the last year, the Revenue has grown by 40.53%.
Measured over the past years, LGND shows a small growth in Revenue. The Revenue has been growing by 6.80% on average per year.
EPS 1Y (TTM)20.8%
EPS 3Y-3.83%
EPS 5Y13.44%
EPS Q2Q%14.29%
Revenue 1Y (TTM)40.53%
Revenue growth 3Y-15.51%
Revenue growth 5Y6.8%
Sales Q2Q%14.68%
3.2 Future
Based on estimates for the next years, LGND will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.29% on average per year.
Based on estimates for the next years, LGND will show a very strong growth in Revenue. The Revenue will grow by 20.16% on average per year.
EPS Next Y22.63%
EPS Next 2Y16.57%
EPS Next 3Y15.36%
EPS Next 5Y14.29%
Revenue Next Year31.46%
Revenue Next 2Y22.03%
Revenue Next 3Y20.53%
Revenue Next 5Y20.16%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 33.15, which means the current valuation is very expensive for LGND.
LGND's Price/Earnings ratio is a bit cheaper when compared to the industry. LGND is cheaper than 79.69% of the companies in the same industry.
LGND is valuated rather expensively when we compare the Price/Earnings ratio to 26.13, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 25.81, the valuation of LGND can be described as expensive.
Based on the Price/Forward Earnings ratio, LGND is valued a bit cheaper than the industry average as 74.48% of the companies are valued more expensively.
LGND's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.35.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.15 | ||
| Fwd PE | 25.81 |
4.2 Price Multiples
LGND's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. LGND is cheaper than 77.08% of the companies in the same industry.
76.04% of the companies in the same industry are more expensive than LGND, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 77.18 | ||
| EV/EBITDA | 163.54 |
4.3 Compensation for Growth
LGND's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as LGND's earnings are expected to grow with 15.36% in the coming years.
PEG (NY)1.46
PEG (5Y)2.47
EPS Next 2Y16.57%
EPS Next 3Y15.36%
5. Dividend
5.1 Amount
No dividends for LGND!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:LGND (11/6/2025, 10:13:12 AM)
200.22
+9.84 (+5.17%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners100.32%
Inst Owner Change-2.48%
Ins Owners1.69%
Ins Owner Change0.43%
Market Cap3.92B
Revenue(TTM)187.58M
Net Income(TTM)-75864000
Analysts84.62
Price Target186.79 (-6.71%)
Short Float %6.17%
Short Ratio6.67
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.98%
Min EPS beat(2)7.61%
Max EPS beat(2)10.36%
EPS beat(4)4
Avg EPS beat(4)14.14%
Min EPS beat(4)4.63%
Max EPS beat(4)33.98%
EPS beat(8)8
Avg EPS beat(8)38.28%
EPS beat(12)12
Avg EPS beat(12)65.25%
EPS beat(16)15
Avg EPS beat(16)61.42%
Revenue beat(2)2
Avg Revenue beat(2)10.64%
Min Revenue beat(2)6.44%
Max Revenue beat(2)14.84%
Revenue beat(4)4
Avg Revenue beat(4)13.45%
Min Revenue beat(4)6.44%
Max Revenue beat(4)24.96%
Revenue beat(8)8
Avg Revenue beat(8)14.01%
Revenue beat(12)11
Avg Revenue beat(12)13.22%
Revenue beat(16)14
Avg Revenue beat(16)14.34%
PT rev (1m)0%
PT rev (3m)27.28%
EPS NQ rev (1m)0%
EPS NQ rev (3m)20.74%
EPS NY rev (1m)0%
EPS NY rev (3m)12.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)18.31%
Revenue NY rev (1m)0%
Revenue NY rev (3m)10.66%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.15 | ||
| Fwd PE | 25.81 | ||
| P/S | 20.92 | ||
| P/FCF | 77.18 | ||
| P/OCF | 74.63 | ||
| P/B | 4.74 | ||
| P/tB | 13.85 | ||
| EV/EBITDA | 163.54 |
EPS(TTM)6.04
EY3.02%
EPS(NY)7.76
Fwd EY3.88%
FCF(TTM)2.59
FCFY1.3%
OCF(TTM)2.68
OCFY1.34%
SpS9.57
BVpS42.27
TBVpS14.45
PEG (NY)1.46
PEG (5Y)2.47
Graham Number75.79
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8% | ||
| ROE | -9.16% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 93.05% | ||
| FCFM | 27.11% |
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)1.42%
ROCE(5y)2.25%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
F-Score5
Asset Turnover0.2
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 5.04% | ||
| Cap/Sales | 0.93% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 259.88% | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.45 | ||
| Quick Ratio | 5.21 | ||
| Altman-Z | 19.84 |
F-Score5
WACC8.84%
ROIC/WACCN/A
Cap/Depr(3y)71.95%
Cap/Depr(5y)50.12%
Cap/Sales(3y)19.71%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.8%
EPS 3Y-3.83%
EPS 5Y13.44%
EPS Q2Q%14.29%
EPS Next Y22.63%
EPS Next 2Y16.57%
EPS Next 3Y15.36%
EPS Next 5Y14.29%
Revenue 1Y (TTM)40.53%
Revenue growth 3Y-15.51%
Revenue growth 5Y6.8%
Sales Q2Q%14.68%
Revenue Next Year31.46%
Revenue Next 2Y22.03%
Revenue Next 3Y20.53%
Revenue Next 5Y20.16%
EBIT growth 1Y-288.32%
EBIT growth 3Y-33.67%
EBIT growth 5YN/A
EBIT Next Year478.11%
EBIT Next 3Y137.22%
EBIT Next 5Y79.19%
FCF growth 1Y-48.59%
FCF growth 3Y10.8%
FCF growth 5YN/A
OCF growth 1Y-51.27%
OCF growth 3Y7.19%
OCF growth 5YN/A
LIGAND PHARMACEUTICALS / LGND FAQ
What is the ChartMill fundamental rating of LIGAND PHARMACEUTICALS (LGND) stock?
ChartMill assigns a fundamental rating of 5 / 10 to LGND.
Can you provide the valuation status for LIGAND PHARMACEUTICALS?
ChartMill assigns a valuation rating of 4 / 10 to LIGAND PHARMACEUTICALS (LGND). This can be considered as Fairly Valued.
How profitable is LIGAND PHARMACEUTICALS (LGND) stock?
LIGAND PHARMACEUTICALS (LGND) has a profitability rating of 4 / 10.
What is the valuation of LIGAND PHARMACEUTICALS based on its PE and PB ratios?
The Price/Earnings (PE) ratio for LIGAND PHARMACEUTICALS (LGND) is 33.15 and the Price/Book (PB) ratio is 4.74.
Can you provide the expected EPS growth for LGND stock?
The Earnings per Share (EPS) of LIGAND PHARMACEUTICALS (LGND) is expected to grow by 22.63% in the next year.